1. Home
  2. NEXM vs BMEA Comparison

NEXM vs BMEA Comparison

Compare NEXM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEXM

NexMetals Mining Corp.

BUY

Current Price

$3.50

Market Cap

83.0M

Sector

N/A

ML Signal

BUY

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.34

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXM
BMEA
Founded
N/A
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.0M
96.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NEXM
BMEA
Price
$3.50
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
82.8K
1.7M
Earning Date
11-13-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.37
$0.87
52 Week High
$10.35
$6.30

Technical Indicators

Market Signals
Indicator
NEXM
BMEA
Relative Strength Index (RSI) 38.97 52.65
Support Level $3.47 $0.95
Resistance Level $3.69 $1.56
Average True Range (ATR) 0.19 0.14
MACD 0.03 0.05
Stochastic Oscillator 22.73 63.93

Price Performance

Historical Comparison
NEXM
BMEA

About NEXM NexMetals Mining Corp.

NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: